Realistic, evidence-based patient recruitment goals are key, Shire

By Gareth Macdonald

- Last updated on GMT

An evidence-based approach to planning during protocol development is key to successful patient recruitment according to Joseph Kim, director of clinical operations at Shire Pharmaceuticals.

Kim spoke with ahead of his presentation at Patient Recruitment Outsourcing 2011​ next month and suggested that, in terms of patient recruitment, the pharmaceutical industry has not always been good at using data.

He explained that assumptions about patient populations made during protocol development can determine inclusion and exclusion criteria despite the lack of supporting data.

Instead, Kim said that drug companies need to define the benefits of a more evidence based approach, citing the high cost of protocol amendments as a useful metric. Then, he continued, they need to adopt a create approach to data collection and analysis.

CRO role and need for investment

Kim also suggested that contract research organisations (CROs) can play an important role in the protocol development process if they can successfully move from the traditional survey-based approach to feasibility to a more data-focused model.

They [CROs] are the builder to the [pharma] architect and the architect needs to know how realistic its designs are​.”

One of the hurdles CROs face in introducing this sort of initiative is that a data-focused approach requires investment which, according to Kim, contractors are sometimes reluctant to do unless such spending generated revenue.

Kim will be covering this and various other aspects of patient recruitment during his presentation at Patient recruitment Outsourcing 2011​ in September. Sign up and attend this event here​.

Related news

Show more

Related products


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers